Publications by authors named "Christopher P Doe"

Claim this Profile
D
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
Lanqi Jia, Robert D Simpson, Jing Yuan, Zhenrong Xu, Wei Zhao, Christopher P Doe

ACS Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.
Jing Yuan, Robert D Simpson, Wei Zhao, Colin M Tice, Zhenrong Xu, Christopher P Doe

Bioorg Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of orally bioavailable alkyl amine renin inhibitors.
Zhenrong Xu, Salvacion Cacatian, Jing Yuan, Robert D Simpson, Lanqi Jia, Christopher P Doe

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases.
Clark A Sehon, Gren Z Wang, Andrew Q Viet, Krista B Goodman, Sarah E Dowdell, Christopher P Doe

J Med Chem· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure.
Beat M Jucker, Christopher P Doe, Christine G Schnackenberg, Alan R Olzinski, Kristeen Maniscalco

J Cardiovasc Pharmacol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production.
Weike Bao, David J Behm, Sandhya S Nerurkar, Zhaohui Ao, Ross Bentley, Christopher P A Doe

J Cardiovasc Pharmacol· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
Robert A Stavenger, Haifeng Cui, Sarah E Dowdell, Robert G Franz, Dimitri E Gaitanopoulos, Christopher P Doe

J Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
Krista B Goodman, Haifeng Cui, Sarah E Dowdell, Dimitri E Gaitanopoulos, Robert L Ivy, Christopher P Doe

J Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.
David J Behm, Gerald Stankus, Christopher P A Doe, Robert N Willette, Henry M Sarau

Br J Pharmacol· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic LXR agonists increase LDL in CETP species.
Pieter H E Groot, Nigel J Pearce, John W Yates, Claire Stocker, Charles Sauermelch, Christopher P Doe

J Lipid Res· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urotensin-II: a novel systemic hypertensive factor in the cat.
David J Behm, Christopher P A Doe, Douglas G Johns, Kristeen Maniscalco, Gerald P Stankus

Naunyn Schmiedebergs Arch Pharmacol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease.
Thomas M Behr, Marinela Berova, Christopher P Doe, Haisong Ju, Christiane E Angermann

Curr Opin Investig Drugs· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetred beagle dogs.
Andrew J Batey, Christopher P A Doe

J Pharmacol Toxicol Methods· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.
David J Behm, Stephen M Harrison, Zhaohui Ao, Kristeen Maniscalco, Susan J Pickering, Christopher P A Doe

Br J Pharmacol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis